Naiyer Rizvi
Medical Oncology · New York, NYNPI 1154392066
Payments from drug & device makers
Across 245 payments — averaging $7716.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$524K
- Merck$434K
- AstraZeneca$300K
- F. Hoffmann-la Roche AG$114K
- Exelixis Inc.$106K
- GSK$90K
- plus $323K from 15 others
Across 17 payments — averaging $784.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Regeneron$4K
- Pfizer$3K
What the payments were for
- Consulting fees$105,29776%
- Speaking & faculty fees$3,9673%
- Travel & lodging$22,54716%
- Food & beverage$6,7455%
- Education$850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 51 | $523,512 |
| Merck | 14 | $434,115 |
| AstraZeneca | 45 | $300,485 |
| F. Hoffmann-la Roche AG | 17 | $113,595 |
| Exelixis Inc. | 2 | $105,990 |
| GSK | 11 | $90,095 |
| E.r. Squibb & Sons, L.L.C. | 22 | $86,853 |
| Pfizer | 9 | $84,242 |
| Amgen | 11 | $60,965 |
| Regeneron | 6 | $21,919 |
| Astrazeneca UK Limited | 11 | $13,430 |
| EMD Serono, Inc. | 5 | $11,970 |
| Eli Lilly | 3 | $10,437 |
| Sanofi | 2 | $6,563 |
| Boehringer Ingelheim | 18 | $5,950 |
| Gilead | 6 | $5,199 |
| Foundation Medicine, Inc. | 5 | $5,092 |
| Janssen Scientific Affairs, LLC | 4 | $4,040 |
| Shionogi Inc | 1 | $4,000 |
| Eisai CO., LTD. | 1 | $1,875 |
| Novartis | 1 | $140 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$18,251
- TAGRISSO$10,311
- IMFINZI$10,072
- TECENTRIQ$5,368
- FOUNDATIONACT$5,006
- FOUNDATIONFOCUS$5,006
- FOUNDATIONONE CDX$5,006
- FOUNDATIONONE HEME$5,006
- FOUNDATIONONE$5,006
- LENVIMA$1,875
- Non-Covered Product$1,492
- GILOTRIF$650
- KEYTRUDA$120
How this compares
$1,890,465 in reported general payments places this provider in the 75th percentile of 498 medical oncology providers in New York.
Other medical oncology in New York
- Robert MotzerNew York$32.8M
- Alan HoNew York$32M
- Michael MorrisNew York$30.4M
- Matthew GalskyNew York$28.1M
- Wungki ParkNew York$25.5M
- Komal JhaveriNew York$22.3M
- Joshua RichterNew York$19.9M
- Jia RuanNew York$19.8M
- Andrea CercekNew York$17.8M
- Amy TierstenNew York$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.